Portal de Periódicos da CAPES

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

2019; Elsevier BV; Volume: 30; Issue: 9 Linguagem: Inglês

10.1093/annonc/mdz197

1569-8041

F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi, Xiang Hu, Xiandong Lin, Q.Y. Zhang, J. Feng, Yi Ba, Y.P. Liu, W. Li, Yongqian Shu, Yi Jiang, Quan Li, J.W. Wang, H. T. Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu,

Cancer Immunotherapy and Biomarkers

High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.